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Background: Vaso-occlusive pain crises (VOCs) are the “hallmark” of sickle-cell disease (SCD) 
and can lead to sympathetic nervous system dysfunction. Increased sympathetic nervous system 
activation during VOCs and/or pain can result in vasoconstriction, which may increase the risk 
for subsequent VOCs and pain. Hypnosis is a neuromodulatory intervention that may attenuate 
vascular and pain responsiveness. Due to the lack of laboratory-controlled pain studies in patients 
with SCD and healthy controls, the specific effects of hypnosis on acute pain-associated vascular 
responses are unknown. The current study assessed the effects of hypnosis on peripheral blood 
flow, pain threshold, tolerance, and intensity in adults with and without SCD.
Subjects and methods: Fourteen patients with SCD and 14 healthy controls were included. 
Participants underwent three laboratory pain tasks before and during a 30-minute hypnosis ses-
sion. Peripheral blood flow, pain threshold, tolerance, and intensity before and during hypnosis 
were examined.
Results: A single 30-minute hypnosis session decreased pain intensity by a moderate amount 
in patients with SCD. Pain threshold and tolerance increased following hypnosis in the control 
group, but not in patients with SCD. Patients with SCD exhibited lower baseline peripheral 
blood flow and a greater increase in blood flow following hypnosis than controls.
Conclusion: Given that peripheral vasoconstriction plays a role in the development of VOC, 
current findings provide support for further laboratory and clinical investigations of the effects 
of cognitive–behavioral neuromodulatory interventions on pain responses and peripheral vas-
cular flow in patients with SCD. Current results suggest that hypnosis may increase peripheral 
vasodilation during both the anticipation and experience of pain in patients with SCD. These 
findings indicate a need for further examination of the effects of hypnosis on pain and vascular 
responses utilizing a randomized controlled trial design. Further evidence may help determine 
unique effects of hypnosis and potential benefits of integrating cognitive–behavioral neuro-
modulatory interventions into SCD treatment.
Keywords: sickle-cell disease, pain, hypnosis, blood
Introduction
Sickle-cell disease (SCD) affects up to 100,000 Americans at a rate of one of every 
500 African-American births.1 Vaso-occlusive pain crises (VOCs) are considered the 
“hallmark” of SCD. VOCs occur frequently and may lead to development of chronic 
pain, such that 30% of sampled patients with SCD have reported pain nearly every 
day.1 It has been proposed that continuous allostatic stress load (eg, recurring VOCs) 
can initiate a cascade of physiological changes in patients who experience recurrent 
pain.2 Enhanced sympathetic nervous system activation, parasympathetic nervous 
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system withdrawal, and subsequent peripheral vaso-occlusion 
in individuals with SCD3 result in hypoxic tissue damage, 
which if recurrent may ultimately lead to changes to the 
peripheral and central nervous systems. Indeed, transgenic 
sickle mice exhibit hyperalgesia and neuronal hypersensitiv-
ity and individuals with SCD show hypersensitivity (lower 
pain thresholds) to thermal stimuli,4 providing support for the 
hypothesis that changes in peripheral and central neuronal 
sensory signaling may lead to changes in pain responsive-
ness.5,6 If this hypothesis is validated, SCD patients with 
frequent7 VOCs may be at higher risk for the development 
of altered pain-response mechanisms and thus at higher risk 
for the development of chronic pain. Therefore, examination 
of interventions that may address factors associated with the 
initiation of VOCs (eg, stress, pain, peripheral blood flow) 
is needed.
Neuromodulatory interventions target cortical pain 
modulation and have been shown to have a favorable effect 
on central and peripheral physiological processes related to 
the experience of acute and chronic pain;8,9 however, limited 
data exist on the effect of neuromodulatory interventions on 
mechanisms underlying VOCs (ie, microvascular stress/pain 
responses) in patients with SCD. Engagement in hypnosis, 
a cognitive-based neuromodulatory intervention, has been 
associated with decreases in acute and chronic pain.8 Specifi-
cally, engagement in hypnosis is associated with changes in 
central neuromodulatory and autonomic processes.9–13
Despite limited studies in SCD samples, preliminary 
evidence suggests that hypnosis may be a promising inter-
vention to mitigate pain and the acute-stress response. One 
study described patients with SCD reporting less pain overall 
as well as during VOCs following a hypnosis intervention.14 
A case study of a longitudinal hypnosis intervention in two 
adolescents with SCD reported that the adolescents had a 
feeling of overall warmth and a flushed appearance, presumed 
to be associated with peripheral vasodilation.15 Other studies 
reported preliminary evidence of hypnosis-induced vasodila-
tation in healthy controls and other pain conditions.14,15 These 
results suggest that hypnosis may be a beneficial  cognitive–
behavioral intervention for individuals with SCD. While 
prior studies have shown promise for hypnosis as a clinical 
tool for pain control in SCD, the mechanisms underlying the 
effects of hypnosis on acute pain in this population remain 
unknown. Because the clinical setting provides significant 
variability in pain experiences, context, and responses, a 
study of mechanisms of the effects of hypnosis on acute 
pain in patients with SCD is best studied in the controlled 
setting of a psychophysiological pain laboratory. Inclusion 
of a comparison non-SCD control group can further provide 
evidence on responses that may be unique to patients with 
SCD. Therefore, the objective of the current study was to 
assess the effects of hypnosis on acute experimental pain 
responses and the corresponding responses in microvascu-
lature in adults with and without SCD.
Specific aims and hypotheses
The first aim of this pilot study was to assess whether base-
line pain responses (ie, pain threshold, tolerance, intensity) 
and peripheral blood flow differed across patients with SCD 
and race-matched healthy controls. The second aim was to 
examine the effect of a brief hypnotic intervention on acute 
experimental pain responsiveness during a thermal pain task, 
as assessed by pain threshold, tolerance, and intensity. The 
third aim was to determine the effects of hypnosis on changes 
in peripheral blood flow during anticipation of the pain task 
and during the pain task itself. Finally, the fourth aim was 
to determine if the effect of hypnosis on pain responses and 
blood flow differed across groups.
We hypothesized that patients with SCD would have 
lower peripheral blood flow at baseline and demonstrate lower 
pain thresholds and tolerance and higher pain intensity. We 
hypothesized that in both groups, pain threshold and toler-
ance would increase and pain intensity would decrease after 
hypnosis. We also hypothesized that peripheral blood-flow 
amplitude would increase in both groups during the anticipa-
tion and experience of the pain tasks following the hypnosis 
intervention. Finally, due to already present vasoconstriction 
and reduced blood flow, we hypothesized that patients with 
SCD would experience more benefit from hypnosis and thus 
exhibit a greater change in blood flow following hypnosis. In 
addition, we expected that patients with SCD would demon-
strate a greater increase in pain threshold and tolerance and 
decrease in pain intensity following hypnosis compared to 
healthy controls.
Subjects and methods
All procedures and methods of the current study were 
approved by the Medical Institutional Review Board of the 
University of California – Los Angeles. This trial is registered 
with ClinicalTrials.gov (NCT02620488).
Participants
Participants with SCD (n=14, eleven females, mean age 34 
years, SD 12.88) and without SCD (n=14, eleven females, 
mean age 37.23 years, SD 17.34) were recruited from vari-
ous locations in the greater Los Angeles area, including the 
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Hypnosis on pain and blood flow in SCD
Cayenne Wellness Center and Children’s Foundation, and 
various community SCD meetings in Los Angeles. Inclusion 
criteria for the participants with SCD were a confirmed diag-
nosis of SS hemoglobin, SC hemoglobin, or S-thalassemia 
hemoglobin. Inclusion criteria for the control population 
were healthy individuals (ie, no chronic illness diagnosis) 
whose race matched that of the SC patients. Exclusion criteria 
included any neurologic disorder that affected sensation, skin 
abnormalities/abrasions over the site of stimulus application, 
and any acute or chronic illness that may have impaired 
safety or lab performance. All participants were screened 
via telephone to determine eligibility. We know of only one 
study looking at changes in peripheral blood flow in disease 
populations,16 and various studies investigating peripheral 
blood flow following hypnotic suggestions.14,17 
We chose our sample size to assess feasibility of the cur-
rent protocol and to see if there was any effect on a clinically 
meaningful outcome that has been specifically implicated 
in the genesis of VOCs, and our sample comparable to past 
studies looking at hypnosis and peripheral blood flow.
Procedure
All procedures were approved by the Institutional Review 
Board of the University of California, Los Angeles and were 
conducted at the Pediatric Pain and Palliative Care Program 
Laboratory. The experimenter and the participant were seated 
in the same room. The participant first provided written con-
sent and completed questionnaires. Next, a pulse-oximetry 
transducer was placed on the participant’s left thumb to assess 
peripheral blood flow. The participant sat quietly for 3 min-
utes, during which baseline peripheral blood-flow data were 
collected. Following the baseline period, the experimenter 
verbally announced, “In a minute, pain task 1 will begin”, 
which marked the start of the pain-anticipation period that 
lasted approximately 1 minute. The first set of pain tasks 
(referred to pre-hypnosis tasks) were then conducted and 
pain threshold and tolerance assessed. This was followed by 
a 3-minute recovery, or washout period, and then followed 
by assessing pain intensity. After the three pain tasks had 
been completed, a psychologist trained in medical hypnosis 
was then brought into the room to engage the participant in 
a 30-minute hypnosis session. After the psychologist had 
delivered hypnotic suggestions for analgesia (referred to as 
post-hypnosis), the three pain tasks were readministered in 
the same order as before hypnosis (with a 3-minute washout 
period following assessment of pain threshold). During the 
second pain task, the participant was receiving booster sugges-
tions from the psychologist. The anticipation period before the 
application of the pain stimulus was investigated because it is 
known that the anticipation of pain has influence over activity 
in the somatosensory cortex, and thus can influence the pain 
experience itself and corresponding physiological responses.18 
A summary of the study phases is depicted in Figure 1. At 
the end of the laboratory session, the psychologist conducted 
a brief exit interview and confirmed that the participant was 
fully alert and able to function cognitively before leaving the 
premises. Compensation was then provided.
Measures
Peripheral blood flow
Peripheral blood flow and the heat signal from the neurosen-
sory analyzer were collected continuously throughout the study 
using the BioPac MP150 system and AcqKnowledge software 
(version 3.9.0) so that the timing of all of the measurements 
was synchronized. Continuous readings for SpO
2
, pulse rate, 
and pulse waveform were monitored using the pulse-oximetry 
transducer placed on the left thumb at 1,000 Hz. The average 
blood-flow amplitude – defined by the distance from trough 
to peak on photoplethysmography – during each study phase 
was used for analyses. Blood-flow data were then normalized 
so that parametric statistical tests could be performed, and thus 
no unit is reported, as they were normalized.
Laboratory pain responsiveness
All nociceptive stimulation was applied using a TSA-II 




Pain threshold Pain tolerance
Washout
Figure 1 Summary of study phases before and after hypnosis.
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Ramat Yishai, Israel). The TSA-II consists of a “thermode” 
(30×30 mm) starting at a temperature of 32°C and reaching 
a maximum temperature of 52°C to prevent tissue damage. 
The thermode was placed on the participant’s right forearm 
(brachioradialis muscle) just below the joint cavity and was 
moved down 25.4 mm after each ramp was delivered. Each 
participant was administered a set of pain tasks twice: before 
and after hypnotic analgesia suggestions. Each set of pain 
tasks consisted of three pain tasks (ie, assessment of pain 
threshold, pain tolerance, and pain intensity; see Figure 1 
for illustration of study procedure). This procedure was 
established in a previous study.19
Pain threshold and tolerance
The pain-threshold and -tolerance tasks consisted of six 
heat ramps. Once the ramp started, temperature rose 1°C 
per second. During the first three ramps, participants indi-
cated when they first perceived the stimulus to be painful, 
which was considered their pain threshold. During the 
last three ramps, participants indicated when they could 
no longer tolerate the pain (ie, pain tolerance). Then, the 
threshold and tolerance ratings were averaged across all 
six trials (three threshold and three tolerance trials), and 
this value was used as the target temperature administered 
during the third task.
Pain intensity
The third task consisted of two heat ramps delivered at the 
aforementioned target temperature. Once the thermode 
reached this temperature, the participant was asked to rate 
his/her pain intensity on a 0–100 numeric rating scale (ie, 
0 = no pain, 100 = worst pain possible). This value was clas-
sified as pain intensity.
Hypnosis intervention
After administration of the first set of pain tasks, the psy-
chologist greeted the patient. The participant was informed 
about the facts and myths about medical hypnosis and was 
provided an opportunity to ask questions. The hypnosis pro-
cedure was divided into five phases: 1) relaxation induction 
to induce a narrowed focus of attention, 2) intensification 
of the focused attention and involvement in imagery using 
a “favorite place” suggestion, 3) pre-pain-task analgesic 
suggestions for personally derived analgesic imagery, 4) pre-
and within-task blood-flow suggestions targeting improved 
peripheral vasodilatation through imagery related to warming 
and water flow, and 5) posttask posthypnotic suggestions for 
continued comfort with an alert mind.
Relaxation induction
After the introduction, the participant was encouraged to sit in 
a relaxed, comfortable position with eyes closed, if so desired. 
The participant was then invited to experience relaxation 
imagery, involving relaxation throughout the body with such 
suggestions as “Allowing all the muscles in the shoulders to 
let go, relaxing, feeling the support of the chair, sinking into 
the chair… letting all the tension drain out of the shoulders”.
Intensification
A deepening elevator exercise was then used, where the par-
ticipant was instructed to imagine going down in an elevator 
and relaxing more deeply with each floor. This was followed 
by instructions to imagine a favorite place, a place that evokes 
feelings of relaxation and ease. The participant was invited to 
experience the sights, smells, and textures of this favorite place, 
eg, “… You inhale and smell all the delicious smells of your 
favorite place. Perhaps it’s a beach, or a mountaintop. Somewhere 
you’ve felt warm and safe and serene and content before. You 
reach down and feel the ground. Is it sand slipping through the 
fingers, or the coolness of new-grown grass? Let’s stay here, in 
this place, for a few moments, while you soak in the sensations.”
Hypnotic analgesia – suggestion 1
Next, consistent with the study by Jensen,20 analgesia sug-
gestions were offered in which the participant was invited to 
imagine his or her own personal pain analgesia. Suggestions 
were offered for this personal analgesia to be experienced as 
a favorite color, a cooling balm, a pill, or any other way the 
subject desired. Feelings of relief and comfort were encour-
aged immediately following use of the analgesia.
Hypnotic analgesia and vasodilatory imagery –  
suggestion 2
The pain tasks were then administered a second time, while 
the hypnotherapist continued to support the participant in the 
experience of relief and comfort, eg, “… perhaps imagining 
feelings of relief throughout the arm, the arm feeling more 
and more comfortable as the medicine spreads”. During the 
pain task, the psychologist continued to provide booster sup-
port to enhance the effects hypnotic analgesia further, eg, “… 
Now imagine the area of the arm experiencing heat, imagine 
it being completely surrounded… or completely filled… with 
a sensation of relief… a pleasant sensation of comfort … you 
might like to picture feelings of relief spreading down the arm. 
Noticing how naturally, how easily, you are able to make the 
arm feel different and much more pleasant… even decreasing 
sensations from that area; as if it were disappearing”.
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Posthypnotic period
After the pain tasks had been completed, the psychologist 
invited the participant to experience warm-bath imagery, 
designed to evoke vasodilatory sensations for a 5- to 7-minute 
posttask recovery period. Instructions included: “This bath, 
just the right kind of warmth. The water soothing muscles, 
opening the body, to relax. Such a calm, pleasant feeling. The 
warm water like liquid therapy, melting away troubles, wash-
ing away cares, allowing the body to relax into an even deeper 
state of well-being”. The participant was then provided with 
sufficient time to return to their normal state. A countdown 
from 10 to 1 was used, with 1 being a state of full awareness 
and alertness. The full script for the hypnosis procedure is 
included in the Supplementary Material.
Data analysis
Shapiro–Wilk tests of normality were conducted on the 
primary-outcome variables (blood flow, pain threshold, pain 
tolerance, pain intensity) to determine appropriate statistical 
tests. Natural log transformations were conducted to normal-
ize abnormal pain-responsiveness data, but the data were 
resistant to transformation. As such, appropriate parametric 
(ie, paired- or independent-sample t-tests) and nonparametric 
(ie, Wilcoxon signed-rank and Mann–Whitney U-tests) mean-
difference tests were used for analyses that included normal 
and abnormal variables, respectively. Independent-sample 
t-tests were utilized to determine if baseline levels differed
across groups. Paired-sample mean-difference tests were
conducted to determine if there was a significant change in
laboratory pain responses and blood-flow amplitude following 
hypnosis. To compare the effect of hypnosis on blood-flow
amplitude across groups, the change in amplitude following
hypnosis was determined by subtracting the mean amplitude
during hypnosis from the amplitude value during each post-
hypnosis task. Independent-sample t-tests were then used to
compare change in blood-flow amplitude across groups. All
significance testing was conducted at α=0.05. Parametric test-
ing used Cohen’s d as the effect size (small = 0.2, medium =
0.5, large = 0.8).19 Nonparametric testing used Pearson’s r as
the effect size (small = 0.1, medium = 0.3, large = 0.5).20 All 
analyses were conducted in RStudio (version 3.2.1).
Results
Preliminary results
The sample consisted of 14 total patients with SCD (eleven 
females, mean age 34 years, SD 12.88) and 14 healthy controls 
(eleven females, mean age 37.23 years, SD 17.34). Age was 
not associated with baseline pain threshold (r=–0.16, p=0.58; 
r=–0.48, p=0.09) or pain tolerance (r=–0.47, p=0.09; r=0.11, 
p=0.7) in the SCD and control groups, respectively. Age was 
associated with baseline peripheral blood flow in patients with 
SCD (r=0.69, p=0.019), but not in controls (r=0.32, p=0.31).
Aim 1: baseline pain threshold, tolerance, 
self-reported pain intensity, and blood 
flow
An independent-sample t-test revealed that there was no 





=-0.25, d=0.09; p=0.81), or inten-
sity (t
25.38
=–0.75, d=0.29; p=0.457). The same test revealed
controls had higher peripheral blood flow during baseline 
than patients with SCD (t
21.17
=2.54, d=1.01; p=0.019), but
there were no group differences during hypnosis (t
19.14
=1.61,
d=0.672; p=0.12). No other differences between groups were 
found across tasks in blood flow. Means of each task across 
groups are reported in Table 1.
Aim 2: effects of hypnosis on pain 
threshold, tolerance, and self-reported 
pain intensity
Paired t-tests and Wilcoxon signed-rank tests were conducted 
within groups to determine the effect of hypnosis on controls 
and patients with SCD for each task. Results revealed that 
Table 1 Laboratory pain sensitivity and peripheral blood flow 
during each phase of the study






Pre-hypnosis pain threshold 43.56 3.95 43.86 3.93
Pre-hypnosis pain tolerance 47.12 2.83 47.39 2.57
Pre-hypnosis pain intensity 31.68 22.44 38.64 26.27
Post-hypnosis pain threshold 45.9 3.81 44.45 3.71
Post-hypnosis pain tolerance 48.48 1.98 47.7 3
Post-hypnosis pain intensity 18.57 18.26 33.46 28.23
Blood flow Controls (n=13) SCD (n=11)
Mean SD Mean SD
Baseline** 0.82 0.07 0.76 0.05
Pre-hypnosis anticipation 1 0.81 0.08 0.76 0.05
Pre-hypnosis pain task 1 0.82 0.05 0.77 0.05
Pre-hypnosis anticipation 2 0.81 0.09 0.76 0.08
Pre-hypnosis pain task 2* 0.81 0.06 0.75 0.08
Hypnosis 0.8 0.05 0.76 0.06
Post-hypnosis anticipation 1* 0.79 0.06 0.82 0.05
Post-hypnosis pain task 1 0.79 0.05 0.79 0.07
Post-hypnosis anticipation 2 0.77 0.09 0.82 0.09
Post-hypnosis pain task 2 0.78 0.08 0.79 0.07
Note: *p<0.05; **p<0.01. Units for blood flow are normalized and thus arbitrary units.
Abbreviation: SCD, sickle-cell disease.
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post-hypnosis pain threshold (median 46.3) was higher than 
pre-hypnosis threshold (median 44.1) in the control group 
(Z=–2.542, r=0.68; p=0.011), but pre- and post-hypnosis pain 
threshold (median 43.8 and 45.5, respectively) did not differ in 
the SCD group (Z=–0.722, r=0.21; p=0.43). Similarly, results 
revealed that pain tolerance significantly increased following 
hypnosis in the control group (t
13
=2.49, d=0.67; p=0.027),
but not in the SCD group (Z=–0.0408, r=0.097; p=0.72). 
Finally, post-hypnosis pain-intensity ratings (median 18.75) 
were lower than pre-hypnosis ratings (median 26.25) in the 
control group (Z=–2.275, r=–0.55; p=0.041). Post-hypnosis 
pain-intensity ratings decreased in the SCD group, as indi-




Aim 3: effects of hypnosis on peripheral 
blood-flow responsiveness
A paired-sample t-test revealed that in the SCD group, 
anticipation-period peripheral blood-flow amplitude was 
significantly higher following hypnosis (t
10
=5.722, d=1.73;
p=0.0002). In the control group, there was no change between 
pre- and post-hypnosis anticipation-period peripheral blood 
flow (t
12
=–0.0207, d=0.06, p=0.84). There were no other
pre- and post-hypnosis differences in each task for either 
group. See Table 2.
Aim 4: effect of hypnosis across groups
An independent-sample t-test across groups revealed that the 
increases in blood-flow amplitude during post-hypnosis pain 
task 1 – anticipation, pain task 1 (trending toward signifi-
cance, moderate effect size), and pain task 2 – anticipation 
period (trending toward significance, moderate effect size) 
were larger in the SCD group compared to controls (t=3.152, 
d=1.242, p=0.004; t=1.704, d=0.68, p=0.1; t=1.403, d=0.56, 
p=0.18). Change in blood-flow amplitude during the pain-
intensity task was similar across groups (Table 3).
Discussion
The current pilot study assessed the effects of a brief hypnosis 
session on acute experimental pain responses and peripheral 
blood flow in adults with and without SCD. Overall, following 
hypnosis, pain threshold and tolerance increased and pain 
intensity decreased in the control group, and in the SCD 
group peripheral blood flow increased to levels comparable 
to controls. Pain-threshold and tolerance levels did not change 
following hypnosis in patients with SCD, but a moderate 
effect size showed decreased pain intensity in this group.
Acute-pain responsiveness
Examination of baseline pain responsiveness revealed that 
there were no differences between controls and adults with 
SCD in respect to pain threshold, tolerance, or intensity. We 
found that following hypnosis, pain threshold and tolerance 
significantly increased and pain intensity decreased in the 
control group. Pain-threshold and tolerance levels did not 
change following hypnosis in patients with SCD. There was 
a trend toward decreased pain intensity in the SCD group, 
and although this decrease was not statistically significant, 
there was a moderate effect in the hypothesized direction. 
Of note, based on previously published clinically significant 
benchmarks for change in pain intensity, the mean decrease 
in pain intensity in the control group reflected a minimally 
Table 2 Effects of hypnosis flow on peripheral blood flow responsiveness
Control SCD
t p d t p d
Pre-hypnosis anticipation period –0.207 0.84 0.06 5.722 0.0002 1.73
Pre-hypnosis pain task –0.01 0.99 0.003 –0.587 0.57 0.18
Post-hypnosis anticipation period 0.187 0.85 0.05 1.294 0.23 0.39
Post-hypnosis pain task 0.255 0.8 0.07 0.719 0.49 0.22
Abbreviation: SCD, sickle-cell disease.
Table 3 Effect of hypnosis on peripheral blood flow
Change in blood-flow amplitude
Post-hypnosis period Control (n=13) SCD (n=11) t p d
Mean SD Mean SD
Pre-hypnosis anticipation period –0.01 0.068 0.06 0.042 –3.152 0.004 1.242
Pre-hypnosis pain task –0.01 0.049 0.02 0.035 –1.704 0.103 0.679
Post-hypnosis anticipation period –0.01 0.088 0.03 0.067 –1.403 0.175 0.561
Post-hypnosis pain task –0.01 0.026 0 0.076 –0.251 0.806 0.11
Abbreviation: SCD, sickle-cell disease.
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important change,23 whereas the SCD group did not reach this 
threshold.24 This pilot study may have had insufficient power 
to detect a significant effect, and there was limited variability 
in pain scores across each group. Future work may benefit 
from including a larger sample size to examine the clinically 
significant effects of hypnosis on pain outcomes.
Another explanation for the lack of reduction in pain 
thresholds and tolerance in the SCD group may be the 
presence of central sensitization resulting in persistent or 
chronic pain. Persistent pain often experienced by individuals 
with SCD2 may result in altered pain perception set points. 
Modulation of neuronal activation thresholds have also 
been observed via TRPV1 channels, which may translate to 
changes in pain sensitivity to thermal stimuli21 and changes 
in the central gain of the somatosensory system.22 However, 
if patients with SCD are exposed to background chronic pain, 
they may use a different reference point to indicate acute-pain 
responses than those who do not have this experience with 
chronic pain. Pain thresholds may be set higher in patients 
with SCD compared to controls, because of either past experi-
ences with significant pain during VOCs or because of under-
lying chronic pain and altered pain perception. Therefore, the 
limited dose of treatment (ie, a single, brief hypnosis session) 
may have not been sufficient to alter acute-pain thresholds 
and tolerance in the face of altered peripheral and central 
pain-modulation systems secondary to pain history or the 
development of chronic pain. Future studies would benefit 
from assessing pain history and the presence of chronic pain 
to determine how these may affect acute-pain responsiveness. 
Mechanisms of acute pain and chronic pain in patients with 
SCD warrant further study.
Peripheral blood flow
Although pain responses in the SCD group did differ sig-
nificantly following hypnosis, the single hypnosis session 
did have a significant effect on peripheral blood flow in 
anticipation of and in response to pain stimulation in the 
SCD group. At baseline, patients with SCD had significantly 
lower blood flow than controls, but these levels increased to 
levels comparable to the control group during post-hypnosis 
tasks, erasing the group differences found at baseline. A 
change in blood flow with hypnosis was not seen in the 
control group. Hypnosis may produce analgesia by engaging 
descending inhibitory pathways from the brain and increas-
ing regional blood flow.23 In the current study, we expected 
blood flow in both groups to increase with hypnosis, but 
blood flow increased only in the SCD group. In this study, 
we demonstrated that hypnosis was beneficial in improving 
peripheral blood flow in anticipation of pain stimulation in 
patients with SCD.
The current findings provide further support that patients 
with SCD exhibit peripheral vascular system dysfunction.24 
Our results indicate that a single brief hypnosis session may 
activate top-down neuromodulatory mechanisms in patients 
with SCD that result in increased vasodilation and peripheral 
blood flow to a degree comparable to that of healthy controls. 
Longitudinal research utilizing multiple hypnosis sessions 
and continuous monitoring of blood flow in a larger sample is 
warranted to examine the efficacy of hypnosis on blood flow 
over time. Of interest is that peripheral blood flow increased 
with hypnosis in anticipation of the pain event in SCD 
patients, even without changes in reported pain responses. 
Exploration of effects of hypnosis on pathways, such as the 
autonomic nervous system (ANS), that can impact peripheral 
blood flow but may not reach conscious awareness in patients 
with SCD warrant further study.
Possible mechanisms
Considering possible mechanisms from a central perspective, 
alterations in brain connectivity in inhibitory pain-control 
networks have been observed during hypnosis.25,26 Specifi-
cally, increased connectivity between the ipsilateral insula 
and bilateral dorsolateral prefrontal cortex has been observed 
during hypnosis in healthy individuals who were highly 
hypnotizable.25 In addition, decreased fractional amplitude 
of low-frequency fluctuation in the dorsal anterior cingulate 
cortex was observed in individuals who were highly hypnotiz-
able, a finding that may represent decreased attention to the 
external environment during hypnosis25 and thus decreased 
pain perception and responsiveness. Results from these 
studies provide more evidence to support the concept that 
hypnosis affects pain-modulatory systems, engages top-down 
neuromodulatory pain circuits, and helps filter out external 
stressors that may be contributing to allostatic stress load (ie, 
pain and anticipation of pain). In the current study, although 
no significant changes were observed in behavioral responses, 
the increase in blood flow despite exposure to stress (ie, a 
pain stimulus) may demonstrate this central pain-modulatory 
mechanism.
In our sample, patients with SCD had lower baseline 
peripheral blood flow compared to healthy controls, which is 
consistent with other literature showing evidence of allostatic 
load and ANS dysfunction in patients with SCD.27 In the cur-
rent study, following a single session of hypnosis, patients 
with SCD exhibited increased peripheral blood flow in antici-
pation of and during pain tasks. This finding  suggests that a 
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single session of hypnosis may affect peripheral vascular pain 
responses modulated by the ANS. Given that ANS-modulated 
peripheral vasoconstriction with stress or pain may increase 
likelihood for vaso-occlusion and VOCs,28–32 further examina-
tion of ANS mechanisms and neuromodulatory treatments 
aimed at addressing pain-related autonomic regulation (eg, 
hypnosis) is warranted.
Additional research is needed to understand the underly-
ing mechanisms of the effects of hypnosis in patients with 
SCD. Specifically, future studies should examine neurally 
mediated systems, such as the ANS (eg, heart-rate vari-
ability and electrodermal activity), and central supraspinal 
parameters (eg, brain imaging) to advance our understanding 
of treatment effects and SCD pain-related pathophysiology 
from a multisystem perspective. Tailoring neuromodulatory 
interventions for the specific needs of patients with SCD 
has the potential to improve treatment and patient outcomes.
Limitations
Limitations in the study should be noted. First, the small 
sample of this pilot study limited statistical power, and 
findings may not generalize to larger samples or broader 
populations. In addition, this pilot study did not include a 
treatment-control condition, which limits our ability to assess 
the success or unique effects of hypnosis. Future work should 
include a treatment-control condition (eg, diaphragmatic 
breathing, distraction) within a randomized controlled trial to 
examine and confirm the specific effects of hypnosis. Future 
studies may also compare hypnosis to other evidence-based 
interventions, such as biofeedback, cognitive–behavioral 
therapy, or therapeutic yoga.33 The current study did not 
examine the effects of hypnosis on clinical pain outcomes 
either, including the frequency and/or severity of VOCs, and 
future work would benefit from assessing these outcomes 
through longitudinal methodology. Further, it is possible that 
more than a single hypnosis session is needed to affect change 
in perception and behavioral responses to acute pain, and the 
examination of the effects of multiple hypnosis sessions on 
pain outcomes is warranted.
In the current study, baseline peripheral blood flow was 
related to age in patients with SCD. This finding is not surpris-
ing, since we would expect that as individuals age they are 
more prone to microvascular pathologies,34 which may impair 
vascular function. Therefore, potential previous vascular dam-
age in our adult sample may have influenced baseline data and 
treatment effects. Sampling of adolescents within a specific 
age range in future studies may help control for potential 
effects of microvascular damage on blood-flow outcomes.
It is also important to note that only thermal sensory 
testing was applied in the current study, and may not be 
generalizable to all types of pain, as thermal pain has dif-
ferent underlying molecular mechanisms compared to other 
types of pain.35 Additional covariates that may influence 
ANS responsiveness and blood flow not included in the 
current analyses (eg, pain history, SCD genotype, history of 
VOCs, heart disease, anxiety, depression, smoking history, 
and medication use) may have had an impact on the current 
findings and should be assessed in future work. In addition, 
the current study did not assess hypnotizability, which has 
been shown to be associated with the effect of hypnosis on 
autonomic response10 and vaso-occlusion.36 The inclusion of 
qualitative post-hypnosis interviews in future work may help 
further explore participants’ experiences and the effect of 
hypnosis. Additionally, investigating the anticipation period 
to unpainful stimuli would help address differences and 
similarities in physiological responses. To help diminish the 
effect of confounding variables, counterbalancing hypnotic 
and nonhypnotic conditions may also help better isolate the 
effect of hypnosis. Finally, the investigator and clinician in 
the current study were not blinded to the patient condition, 
which may have introduced bias. Future work will aim to 
blind the investigator in the room or place the investigator 
in a different room to collect psychophysiological measures.
Conclusion
This study demonstrated that the amount of peripheral blood 
flow in anticipation of pain in adults with SCD increased 
following a single, 30-minute hypnosis session. There was 
a trend toward decreased perceived pain in SCD patients as 
well. Given that peripheral vasoconstriction and blood flow 
likely play a role in the development of VOCs, these findings 
provide initial support for further study of mechanisms and 
effects of neuromodulatory interventions in pain management 
for patients with SCD. Collectively, our results suggest that 
patients with SCD may need targeted treatment that addresses 
both central and peripheral neurovascular processes. Future 
work will determine if engagement in hypnotherapy affects 
long-term pain and VOC outcomes in patients with SCD, 
as well as examine pathways through which these effects 
take place.
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